Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.

@article{Shepherd1987CyclophosphamideDA,
  title={Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.},
  author={F A Shepherd and William K. Evans and Ronald Eric Maccormick and Ronald Feld and Jonathan C Yau},
  journal={Cancer treatment reports},
  year={1987},
  volume={71 10},
  pages={941-4}
}
For two chemotherapy regimens to be truly non-cross-resistant, each should be active as first-line therapy and also as second-line therapy. The effectiveness of both cyclophosphamide, doxorubicin, and vincristine (CAV) and etoposide and cisplatin (VPP) in previously untreated patients with small cell lung cancer has been well-documented. Also, VPP has caused tumor regression in up to 50% of patients when used as second-line therapy after CAV. The effectiveness of CAV after progression or… CONTINUE READING